Healthy Clinical Trial
Official title:
A Single-center, Randomized, Double-blinded and Placebo-controlled Clinical Study in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability of LXI-15028 After Receiving Escalating Single Oral Doses of LXI-15028 at 50 mg, 100 mg and 200 mg and Multiple Oral Doses of LXI-15028 at 100 mg
NCT number | NCT03458650 |
Other study ID # | NE821605 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | March 19, 2018 |
Est. completion date | May 8, 2018 |
Verified date | March 2018 |
Source | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
"This study is a single-center, randomized, double-blinded and placebo-controlled trial designed not only to assess pharmacokinetics, safety and tolerability of LXI-15028 but also to evaluate the pharmacokinetic characteristics of main metabolite M1 in vivo in 38 healthy adult Chinese subjects after receiving escalating single oral doses of 50 mg, 100 mg and 200 mg and multiple oral doses of 100 mg of LXI-15028.
Status | Completed |
Enrollment | 38 |
Est. completion date | May 8, 2018 |
Est. primary completion date | April 23, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - The subjects should voluntarily participate in this trial and sign the informed consent form prior to conducting any trial-related procedures; - Gender: male or female healthy subjects; Age: 18~45 years old (including 18 and 45 years old); - The body weight should be equal or greater than 50.0 kg for male and 45.0 kg for female. Body weight index (BMI)= body weight (kg)/[height(m)×height(m)], should be within the range from 19 to 25 (including 19 and 25); - In the past three years, no history or presence of cardiovascular, hepatic, renal, respiratory, hematological and lymphatic, endocrine, immunological, mental, neurological and gastrointestinal disease; no history of surgery; - The subjects (including males and females) agree to use medically approved contraceptive methods during the trial period and within 3 months after the end of the trial in order to avoid pregnancy; medically approved contraceptive methods include intrauterine device, physical barrier (male condom, female condom), subcutaneous implant, sustained-release contraceptive, bilateral salpingectomy, bilateral tubal ligation, bilateral vas ligation, etc.; - The subjects agree not to donate sperms (males) or ova (females) at least 7 days before the first dose, during the study and within 3 months after ending of this study. Exclusion Criteria: - The subjects with allergic constitution, for example those with bronchial asthma, allergic to food or pollen, allergic to two or more drugs or those with known history of allergy ; or the subjects with any serious adverse response to Proton Pump Inhibitor or P-CABs previously (e.g., omeprazole, rabeprazole, lansoprazole and TAK-481 ), or known allergy to penicillins or cephalosporins; - The investigator determines that it may potentially affect absorption, distribution, metabolism or elimination of investigational drug (e.g. organ dysfunction); - The subjects with a history of drug abuse or drug abuse screening positive; - The subjects received any drugs (including prescription drugs, Over-The-Counter drugs, herbal medicines, etc.) within 1 month before the screening or are taking drugs, especially CYP3A inhibitor or inducer (see Appendix 1); - The subjects with clinical significant physical examination abnormalities determined by investigator; - Heart rate<50 beats/min or >100 beats/min or QTc interval prolonged (male QTcF=430ms, female QTcF=450ms) or QRS=120 msec or other clinically significant ECG abnormalities; 7) The subjects with sitting blood pressure: systolic pressure <90mmHg or = 140mmHg, diastolic pressure =90mmHg or <60mmHg, which shows clinical significant abnormalities determined by investigators - The subjects with any biomarker value of Aspartate aminotransferase (AST),Alanine aminotransferase(ALT), Alkaline phosphatase(ALP),r-Glutamyl Transferase (r-GT), total bilirubin, creatinine above the upper limit of normal or with other clinical significant laboratory examination abnormalities judged by investigators - The subjects with presence of one of the following infectious diseases; 1. Virological determination indicates hepatitis B virus surface antigen (HBsAg) positive or anti-hepatitis C virus antibody positive; 2. Acquired human immunodeficiency virus determination indicates infection; (anti-human immunodeficiency virus antibody positive) 3. Treponema pallidum infection (anti-treponema pallidum-specific antibody positive). - Currently smoking or quitting smoking less than 3 months before screening or tobacco screening positive; - Chronical alcohol user within 5 years prior to screening, or alcohol consumption of more than 14 unit alcohol per week (1 unit alcohol equal to 360 mL beer, or 150 mL grape wine, or 45 mL wine of 40 degree) within 6 months prior to screening; - Alcohol screening test positive or alcohol intake within 72 h prior to screening; - Daily drinking a large amount (above 1000 mL) of tea, coffee, cola and/or caffeine-containing beverages within 6 months prior to screening; - Taking xanthine-containing or caffeine-containing food or beverages (including chocolate, tea, coffee and cola, etc.) from 48 hours prior to screening; - Taking grapefruit, lime, carambola or any food or beverages made from them within 7 days prior to screening; - Female subjects with blood pregnancy test positive or during lactation - Difficulty in blood sampling, or has relevant history, symptoms or signs of blood sampling difficulty; - Transfusion treatment or blood donation or massive blood loss (exceeding 450 mL) judged by investigators within 3 months prior to screening; - Participation in any other clinical study within 3 months prior to screening; - Participation in the planning or execution of this study (e.g., the sponsor or staff in the site); - Inappropriate to participate in this study for any reason according to the medical judgment of investigators. |
Country | Name | City | State |
---|---|---|---|
China | Huashan Hospital, Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetic parameter: Cmax | The maximum plasma concentration (Cmax) after single dose LXI-15028 | 72 h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: Tmax | The peak time (Tmax) after single dose LXI-15028 | 72 h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: T1/2 | The elimination half-life T1/2 after single dose LXI-15028 | 72 h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: Kel | The eliminate rate constant after single dose LXI-15028 | 72 h after receiving single oral dose | |
Primary | Pharmacokinetic parameter:Mean Residence Time(MRT) | The mean residence time after single dose LXI-15028 | 72 h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: Area Under plasma Concentration(AUC 0-24h) | The area under plasma concentration -time curve from 0 time ot 24 h after single dose LXI-15028 | 24h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: AUC 0-last | The area under plasma concentration- time curve from 0 time to sampling time of the last measurable concentration after single dose LXI-15028 | 72h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: AUC 0-inf | The area under plasma concentration-time curve from adminstration (0)to infinity after single dose LXI-15028 | 72h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: Vd/F | The apparent volume of distribution after single dose LXI-15028 | 72h after receiving single oral dose | |
Primary | Pharmacokinetic parameter: Css min | The trough concentration at steady state(Css min) after multiple doses | predose at day 8, 9, and 10, 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: Css max | The peak concentration at steady state (Css max) after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: Css av | The average concentration at steady state (Css, av)after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: Tss max | The peak time after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: Tss,1/2 | The steady-state clearance half-time after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: CLss/F | Total body clearance after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: coefficient of fluctuation (DF) | coefficient of fluctuation after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: Area Under plasma Concentration at steady state (AUC ss) | The area under plasma concentration-time curve at steady state after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Pharmacokinetic parameter: Rac | The accumulation coefficient after multiple doses | 72 h after receiving last multiple oral doses | |
Primary | Physical examination value of single dose | This measure is a composite. Evaluate safety and tolerability of single dose in Physical examination that should cover the head, eyes, ears, nose, throat, cardiovascular system, skin, musculoskeletal, respiratory system, digestive system, urinary system and nervous system and changes of each item from the baseline are summarized. The measurement results of each subject are summarized by different severity. All physical examination results during this trial will be listed in details. | Baseline to Day 4 after receiving single oral dose | |
Primary | Vital signs value of single dose | The measure is a composite.Evaluate safety and tolerability of single dose in Vital signs value that including blood pressure (Systolic blood pressure/Diastolic blood pressure), pulse, body temperature,each vital sign examination values at each evaluation time point and their changes relative to the baseline will be summarized. All vital sign results should be listed. The listed vital signs are compared with normal ranges to determine whether is abnormal. The examination results that are divided into higher than normal range, normal and lower than normal range will be summarized by number of cases (n) and percentage (%). The results of abnormalities(> or < normal range) are listed. | Up to 3weeks | |
Primary | 12-lead ECG value of single dose | Evaluate safety and tolerability of single dose in 12-lead ECG value that including ventricular rate (beats/min), PR interval (ms), QRS (ms) , QT(ms),QTc (ms), the examination results of each ECG parameters and their changes from baseline will be summarized at each time point. Meanwhile, all 12-lead ECG examination results will be listed in details. | Up to 3 weeks | |
Primary | Blood routine value of single dose | Evaluate safety and tolerability of single dose in blood routine value that including White blood cells (WBC), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), platelet, neutrophils, lymphocytes, monocytes, eosinophils, basophils, absolute neutrophil counts (ANC);and list all the result. | Baseline to Day 4 after receiving single oral dose | |
Primary | Urine routine value of single dose | Evaluate safety and tolerability of single dose in urine routine value that including specific gravity, pH, proteins, ketone,occult blood; and list all the result. | Baseline to Day 4 after receiving single oral dose | |
Primary | Blood coagulation value of single dose | Evaluate safety and tolerability of single dose in blood coagulation value that including International normalized ratio (INR), activated partial thromboplastin time (aPTT), prothrombin time (PT); and list all the result. | Baseline to Day 4 after receiving single oral dose | |
Primary | Blood biochemistry value of single dose | Evaluate safety and tolerability of single dose in blood biochemistry value that including Cholesterol, total proteins, albumin, total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (?-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result. | Baseline to Day 4 after receiving single oral dose | |
Primary | Adverse events of single dose | The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all TEAE, investigational drug-related TEAE, Serious Adverse Event, investigational drug-related SAE, and TEAE causing premature withdrawal from this study will be separately summarized by different dose groups, including number of subjects experiencing Adverse Event, percentage and number of AE cases. The summary results are sorted according to the ranking number of cases of all subjects experiencing AE. All AE and SAE are listed by different dose groups. | Up to 3 weeks | |
Primary | Physical examination value of multiple doses | The measure is a composite. Evaluate safety and tolerability of multiple doses in Physical examination that should cover the head, eyes, ears, nose, throat, cardiovascular system, skin, musculoskeletal, respiratory system, digestive system, urinary system and nervous system and changes of each item from the baseline are summarized. The measurement results of each subject are summarized by different severity. All physical examination results during this trial will be listed in details. | Baseline to Day 21 after receiving the first dose | |
Primary | Vital signs value of multiple doses | The measure is a composite.Evaluate safety and tolerability of multiple doses in Vital signs value that including blood pressure(Systolic blood pressure/Diastolic blood pressure), pulse, body temperature.Each vital sign examination values at each evaluation time point and their changes relative to the baseline will be summarized. All vital sign results should be listed. The listed vital signs are compared with normal ranges to determine whether is abnormal. The examination results that are divided into higher than normal range, normal and lower than normal range will be summarized by number of cases (n) and percentage (%). The results of abnormalities(> or < normal range) are listed. | Baseline to Day 21 after receiving the first dose | |
Primary | 12-lead ECG value of multiple doses | Evaluate safety and tolerability of multiple doses in 12-lead ECG value that including ventricular rate (beats/min) ,PR interval (ms), QRS (ms) ,,QT(ms), QT interval (QTc )(ms). The examination results of each ECG parameters and their changes from baseline will be summarized at each time point. Meanwhile, all 12-lead ECG examination results will be listed in details. | :Baseline to Day 21 after receiving the first dose | |
Primary | Blood routine value of multiple doses | Evaluate safety and tolerability of multiple doses in blood routine value that including White blood cells (WBC), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), platelet, neutrophils, lymphocytes, monocytes, eosinophils, basophils, absolute neutrophil counts (ANC); and list all the result. | Baseline to Day 21 after receiving the first dose | |
Primary | Urine routine value of multiple doses | Evaluate safety and tolerability of multiple doses in urine routine value that including specific gravity, potential of hydrogen (pH), proteins, ketone,occult blood; and list all the result. | Baseline to Day 21 after receiving the first dose | |
Primary | Blood coagulation value of multiple doses | Evaluate safety and tolerability of multiple doses in blood coagulation value that including International normalized ratio (INR), activated partial thromboplastin time (aPTT), prothrombin time (PT); | Baseline to Day 21 after receiving the first dose | |
Primary | Blood biochemistry value of multiple doses | Evaluate safety and tolerability of multiple doses in blood biochemistry value that including Cholesterol, total proteins, albumin, total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (?-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result. | Baseline to Day 21 after receiving the first dose | |
Primary | Adverse events of multiple doses | The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all treatment-emergent adverse event (TEAE), investigational drug-related TEAE, serious adverse event (SAE), investigational drug-related SAE, and TEAE causing premature withdrawal from this study will be separately summarized by different dose groups, including number of subjects experiencing AE, percentage and number of adverse event (AE) cases. The summary results are sorted according to the ranking number of cases of all subjects experiencing AE. All AE and SAE are listed by different dose groups. | Up to 6 weeks | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Cmax | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: peak concentration Cmax | 72 h after receiving single oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Tmax | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: peak time Tmax | 72 h after receiving single oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): T1/2 | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: elimination half-life T1/2 | 72 h after receiving single oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Kel | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: eliminate rate constant | 72 h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): MRT | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: mean residence time | 72 h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): AUC 0-24h | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to 24 hours | 24 h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): AUC 0-last | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to the last measurable concentration | 72 h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): AUC 0-inf | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to infinity | 72h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): CL/F | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single dose:apparent total clearance | 72h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Vd/F | Major metabolite (M1) of LXI-15028 Plasma PK parameters of single dose: apparent volume of distribution | 72h after receiving single oral dose | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Css, min | Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: trough concentration at steady state | :predose at day 8, 9, and 10, 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Css, max | Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses:peak concentration at steady state | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Css, av | Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: average concentration at steady state | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Tss, max | Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: peak time | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Vss/F | Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:apparent volume of distribution at steady state | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): tss,1/2 | Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:steady-state clearance half-life | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): CLss/F | Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:total body clearance | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): DF | Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses: coefficient of fluctuation | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): AUCss | Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses: area under plasma concentration-time curve at steady state | 72 h after receiving last multiple oral doses | |
Secondary | Pharmacokinetic parameter of major metabolite(M1): Rac | Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: accumulation coefficient | 72 h after receiving last multiple oral doses |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |